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Long-lived hematopoietic stem cells (HSCs) are cells that self-renew and generate all 
mature blood cell types.1  HSCs reside in a microenvironment composed of multiple distinct 
cellular niches that provide critical signals for adhesion, survival, quiescence and proliferation.2  
The mechanisms by which these niches regulate the long-term fate of HSCs are incompletely 
known but are critical to our understanding of leukemogenesis and reconstitution of hematopoiesis 
after hematopoietic stem cell transplantation (HSCT).  Prior studies have shown that the 
endothelial cell niche of the developing zebrafish can be modulated by overexpression of the 
angiogenic chemokine receptor, cxcr1, to increase its capacity to support hematopoietic stem and 
progenitor cells (HSPCs) in short term assays.3   In preliminary data from the Blaser Laboratory, 
219 candidate genes with differential expression between niche- and non-niche endothelial cells 
were identified.  A gain of function screen identified the zebrafish protein kinase C (PKC) isoform 
prkcda (PKC delta a) as a positive regulator of short- and long-term HSC fate.  Prkcda is a member 
of related proteins that are important second messengers for extracellular communication signals.  
I hypothesized that PKC isozymes have specific roles in regulating HSC fate by affecting the 
function of the endothelial cell niche.  RNA sequencing showed no significant differences in 
expression of any of these isozymes in niche endothelial cells compared with non-niche endothelial 
cells.  To functionally test the role of each, I generated zebrafish with transgenic expression of the 
isozyme in the niche and found no significant differences in HSC numbers.  To begin to understand 
the requirement for each isozyme, I made loss of function mutants using CRISPR/Cas9 which will 
be studied more in the future.  Elucidation of the role of PKC signaling within the hematopoietic 
microenvironment may enhance our understanding of leukemogenesis and hematopoietic 
reconstitution after HSCT.  
Introduction 
PKCs are serine and threonine kinases capable of regulating cell proliferation, gene 
expression, migration, and apoptosis.4  Twelve PKC isozymes are known,5 each categorized based 
on their structure and unique substrate targeting preferences.6  Three PKC subgroups are 
categorized by their unique activation signals: conventional PKC (α, βI, βII, and γ) respond to 
diacylglycerol (DAG), phosphatidylserine (PS), and Ca2+; novel PKC (δ, ε, η, θ, and μ) respond to 
DAG and PS; and atypical PKC (ζ, λ, and ι) respond to neither DAG nor Ca2+ but require PS.5-7  
Abnormal PKC expression in humans has been implicated in cancer and heart disease.5,8 
The PKC structure includes a regulatory amino-terminus and a catalytic carboxy-terminus 
(Figure 1).9  Way et al6 noted that PKC isoforms vary in structure predominantly in the conserved 
region.  Conventional PKCs contain four conserved and five variable regions.10  Two of the 
conserved domains, C1 and C2, are regulatory and interact with DAG, PS, and Ca2+ for binding to 
the lipid bilayer of the cell.6  The sole C1 region of atypical PKCs does not bind DAG due to the 
basicity of its binding residues.11,12  Unlike conventional PKCs, the C2-like region of novel PKCs 
Figure 1. Three PKC subgroups containing conserved, PB1, and kinase domains. 
does not bind Ca2+.13  The catalytic C3 region binds ATP, and the C4 region, also catalytic, is 
involved in the phosphorylation of substrates.6  Both C3 and C4 are part of the conserved kinase 
domain in the conventional, novel, and atypical PKC subgroups.14  Cellular processes associated 
with PKC activation include signaling via the G-protein coupled receptor (GPCR) second 
messenger cascade, extracellular ligand binding, communication with different PKCs, and other 
molecular binding or signaling.15-18 
In conventional PKC signaling, phospholipase C (PLC) and G-protein coupling are 
initiated upon first messenger binding to the GPCR.19  One example of first messenger signaling 
includes the cxcl8 chemokine and associated cxcr1 and cxcr2 receptors.  The G-protein associated 
receptors bind the chemokine and activate the signaling cascade via PLC.19  Cxcl8 and cxcr1 
expression in zebrafish endothelial cells has been shown to enhance HSPC colonization of the 
caudal hematopoietic tissue (CHT).3  Likewise, cxcr4 can bind the chemokine ligand cxcl12, 
activating a cascade through PLC.20  Cxcr4 expression occurs in HSCs and endothelial cells,21 and 
the cxcl12/cxcr4 signaling pathway has been associated with cell adhesion, cell proliferation and 
cancer metastasis.22  The chemokine receptors and related signaling cascades are potential targets 
for cancer treatments,23 which can inhibit PKC activation.17 
Activated PLC separates phosphatidylinositol 4,5-bisphosphate (PIP2) into second 
messengers, DAG and inositol trisphosphate (IP3).24  IP3 will then enable Ca2+ ion release from the 
endoplasmic reticulum.25  Ca2+ binds the regulatory C2 region, attracting PKC to the anionic PS of 
the phospholipid bilayer.26  PKC’s C1B region binds DAG and PS at the membrane, thereby 
converting the autoinhibited PKC into an active enzyme following the removal of a 
pseudosubstrate from the kinase.27  The conventional PKC is then able to phosphorylate proteins 
and conduct further signaling within the cell.27  
Unlike conventional and novel PKCs, atypical PKCs utilize a PB1 region in order to bind 
protein scaffolds.28  Whereas conventional PKC isozymes bind DAG prior to pseudosubstrate 
removal from the kinase, protein scaffolds containing a PB1 domain bind the atypical PKC PB1 
domain to activate the kinase.28  Examples of protein scaffolds include p62 and Par6,28 which 
enable the PKC’s open confirmation.29  Placement of the PKC and corresponding substrate on the 
scaffold improves phosphorylation since atypical PKCs maintain slow reaction rates.11 
Disturbances of PKC isoform signaling cascades can have implications for 
leukemogenesis.  According to Nakagawa et al,30 a PKCα dominant-negative mutation in 
hematopoietic progenitor cells (HPC) of a murine fetal liver resulted in B lymphocytes 
transformation, resembling phenotypic B cells found in B-Cell Chronic Lymphomatic Leukemia 
(B-CLL).  Dominant negative PKCα plasmids were introduced to the HPCs via a retrovirus and 
compared with MIEV control cells.  PKCα mutation caused the proliferation of these HPCs, which 
was 1.5x greater than that of the control, during the beginning stages of B-cell transformation.  
Notably, B cells expressing the mutation survived without IL-7 growth and OP9 stromal factors 
while 3x more control cells underwent apoptosis under similar conditions.  These findings indicate 
a unique role for PKCα in the transformation of B-cells.30 
PKCδ (prkcda/b in zebrafish) supports cellular apoptosis under certain conditions,31 and 
this isozyme may be downregulated in some forms of cancer.32  Apoptosis of cells is associated 
with the phosphorylation of tyrosine (Tyr), which activates PKCd.31  Phosphorylation of Tyr-64 
and Tyr-155,33 as well as Tyr-311 and Tyr-332,34 residues in PKCδ are associated with apoptosis.  
Chemotherapy is known to cause PKCδ translocation to the nucleus and disrupting this 
translocation has resulted in the inhibition of cellular apoptosis caused by etoposide.33  The 
phosphorylation sites related to apoptosis in etoposide treatments are Tyr-187 and Tyr-64.33  Tyr-
155, Tyr-187, and Tyr-64 are located in the regulatory region,33 and Tyr-311 lies within the hinge 
domain, which is located between PKCδ’s catalytic and regulatory regions.34  Additionally, 
chromosome 3p, which houses the PKCδ gene, is associated with tumor suppression.35 
PKCε is linked to cell survival and proliferation.36  Cell proliferation is regulated by the 
RAF1 kinase, which begins the signal cascade involving MEK and ERK phosphorylation.37  
Overexpression of the PKCε isoform in HSCs has been shown to offer protection against 
apoptosis.36  PKCε overexpression has resisted etoposide-induced apoptosis in Non-Small Cell 
Lung Cancer (NSCLC) cells.38  Increased expression of the PKCε isoform has been discovered in 
both breast37 and prostate cancers.40  Murine studies involving prostate-specific lines showed that 
contrary to PKCα and PKCδ expression where the prostate was normal, the experimental group 
experienced preneoplastic lesions in the prostate upon elevated PKCε expression.41 
PKCλ/ι is an atypical PKC that can serve to promote or suppress tumors, depending on the 
microenvironment.42  PKCλ/ι has been linked to tumor initiation in human Lung Adenocarcinoma 
lines in which PKCλ/ι phosphorylates ELF3, resulting in NOTCH3 expression.  Inhibition of this 
signaling pathway was found to prevent tumor formation in vivo.43  Furthermore, Justilien et al 
showed that by preventing Ect2 expression in the PKCλ/ι-Ect2-Rac1-NPM signaling pathway, 
tumor formation in murine lungs could be inhibited.44  Later in cancer development and depending 
on the microenvironment context, however, PKCλ/ι expression may support tumor suppression.42 
The isoform’s underexpression in this case can lead to proliferation and tumorigenesis.42 
The whole genome duplication in zebrafish has resulted in prkc gene paralogs, including 
prkcaa/b (PKC alpha a/b) and prkcba/b (PKC beta a/b), requiring analysis of differing expression 
patterns.45  Preliminary studies performed by the Blaser Lab have shown that prkc isozyme impacts 
on HSPC engraftment within the endothelial cell 
niche can be ascertained using the zebrafish model.  
Zebrafish embryos were generated carrying two 
transgenic reporter genes: kdrl:GFP marking all 
endothelial cells and lyve1b:DsRed, marking the 
endothelial cells of the hematopoietic niche (Caudal 
Hematopoietic Territory, CHT, Figure 2).  Double 
transgenic embryos were dissociated, and niche and non-niche endothelial cells were isolated by 
FACS.  Bulk RNA sequencing was performed on 
the sorted cells and 219 differentially regulated 
genes were identified between the two cell types 
(Figure 3).   
A gain of function screen was performed by 
expressing candidate differentially regulated genes 
within the hematopoietic niche using a niche-
specific enhancer element identified upstream of 
the E selectin gene (sele).  Expression constructs were injected into Runx1:GFP embryos at the 
single cell stage.  These fish carry an HSPC-specific fluorescent reporter transgene.  
Microinjection of an empty vector into clutchmate embryos served as a control.  In both 
experimental and control groups, expression of the microinjected plasmid was identified by 
coexpression of a fluorescent mCherry reporter.    Compared to the sele:mcs-2A-mCherry control 
injections, animals with a sele:prkcda-2A-mCherry construct had significantly more HSCs within 
Figure 3. Flow cytometry and bulk RNA 
sequencing of differentially regulated genes. 
Figure 2. Gene expression in non-
niche and niche endothelial cells. 
the CHT (5.4 ± 1.0 vs 2.5 ± 0.4, p  = 0.01, Figure 4).  In 
order to understand the effects on long-term HSC fate and 
clonal diversity, genetically barcoded GESTALT embryos 
were microinjected with the sele:prkcda-2A-mCherry or 
control plasmids.  Beginning at 3 months post-fertilization, 
peripheral blood was sampled, and genetic barcodes were 
amplified and sequenced to determine the number of 
phylogenetically distinct HSCs contributing to 
hematopoiesis.  Animals injected with the sele:prkcda-2A-mCherry expression constructs had 
significantly greater phylogenetic diversity compared to control animals from 6 to 12 months post-
fertilization (Figure 5).  These results 
suggested that the increased HSCs 
resulting from prkcda overexpression in 
the CHT led to a greater clonal diversity 
throughout life.  The overall aim of this 
thesis project is to better understand the 
role of other PKC isoforms in controlling 
HSC clonal diversity via expression in the 
CHT. 
Materials and Methods 
Animals 
Runx1:GFP, GESTALT, and casper zebrafish were kind gifts of Leonard Zon.  Animals 
were housed in the OSUCCC Aquatic Facility in automated recirculating racks (Tecniplast) using 
Figure 5. Dysregulated niche expression of prkcda 
increases HSC clonal diversity 
Figure 4. HSPC quantification 
within CHT.  
standard husbandry practices (Westerfield, The Zebrafish Book:  A Guide for the Laboratory Use 
of Zebrafish (Danio rerio)).  All experiments were performed under IACUC protocol 
2018A00000012.   
Cloning 
Coding sequences for PKC isoforms were identified in Ensembl (http://www.ensembl.org).  
Primers were designed to amplify the primary transcript according to APPRIS criteria, adding a 
consensus Kozack sequence (CACC) prior to the first codon and removing the stop codon.  Total 
RNA was harvested from 72 hpf zebrafish embryos and cDNA made by reverse transcription 
(Superscript IV, Invitrogen).  PKC coding sequences were amplified and cloned by Topo reaction 
into SD/D Topo Gateway-compatible middle entry vectors (Invitrogen).  LR Clonase reactions 
were performed, according to the manufacturer’s instructions, at 0.5X scale using p5e-sele-792 (5’ 
entry), p3e-2A-mCherry (3’ entry) and 394 (Tol2 compatible backbone) plasmids.  Final 
expression constructs were screened by restriction digest and confirmed by whole plasmid 
sequencing (MGH DNA Core). 
Embryo microinjection 
Tol2-based expression constructs were used for all transgenesis experiments.  Tol2 is a 
zebrafish retrotransposon element and all expression constructs carry LTR integration sequences 
flanking the regions of interest.  Tol2 mRNA was synthesized (mMessage mMachine) and 
coinjected with expression constructs to facilitate integration (100 pg per injection).  Injection 
mixes were generated in order to deliver 20 pg plasmid DNA in 1 nL injection volume.  Following 
microinjection, embryos were incubated at 28 °C.   
For CRISPR/Cas9 injections, high-efficiency sgRNA sequences were identified using 
ChopChop (https://chopchop.cbu.uib.no/).  Commercially-prepared sgRNA CRISPR guides 
targeting prkcba, prkcea/b, prkcda/b, prkcg, and prkcha (Horizon Discovery), were injected with 
recombinant Cas9 enzyme (New England Biolabs) into the mutant casper zebrafish line.   
Microscopy and Image analysis 
At 72 hpf, embryos were anesthetized with tricaine, mounted in agarose and imaged on a 
Keyence BZX-700 digital fluorescence microscope.  Images were obtained at 10X magnification 
using 2-micron Z-slices, acquiring 3 Z stacks per animal to cover the entire CHT.  Images were 
stitched and maximum intensity projections were generated using Keyence software.  Images were 
analyzed in ImageJ.  Each image was scored in a blinded fashion and confirmed by an independent 
evaluator.  
Mutation genotyping  
To confirm CRISPR guide mutation frequency in F0 CRISPR mutants, zebrafish embryos 
were pooled, and genomic DNA purified using the Zymo DNA prep kit.  200 to 300 bp amplicons 
were generated using flanking primers and submitted for next generation sequencing.  Sequencing 
results were analyzed using a custom informatics pipeline.  Adult F1 generation zebrafish were 
genotyped by finclip; PCR products were 
generated with sample indices, pooled, 
sequenced and analyzed in a similar fashion. 
 
Results 
Expression of PKC isoforms in niche-derived 
and non-niche-derived endothelial cells. 
RNA sequencing data from kdrl:GFP+;lyve1:DsRed+ niche-derived endothelial cells and 
kdrl:GFP+;lyve1:DsRed- non-niche-derived endothelial cells was queried to identify expression 
Figure 6. Differential expression of PKC in non-
niche and niche endothelial cells. 
of all known PKC isoforms.  Only prkcda showed significantly differential expression between 
these cell types (Figure 6) 
Anatomic expression pattern of pkcda in 72 hpf zebrafish embryos 
Whole mount in situ hybridization was 
performed to determine the expression 
pattern of prkcda in zebrafish embryos at 72 
hpf.  This showed expression in the heart and 
otic vesicles.  No expression was detected in 
the CHT (Figure 7). 
Gain of function testing 
Functional testing was performed using sele:PKC 
expression constructs.  A total of 315 Runx1:GFP 
animals were microinjected with these constructs 
or empty vector control constructs and imaged at 
72 hpf.  The number of HSPCs within the 
endothelial cell niche was quantified.  The genes 
tested included prkcaa, prkcdb, prkchb, and prkcz, 
corresponding to PKC alpha a, PKC delta b, PKC 
eta b, and PKC zeta.  No significant difference in 
HSPC numbers was found between any of the 
PKC groups and their corresponding controls 
(Figure 8).   
 
Figure 8. HSPC quantification of prkcaa, 
prkcdb, prkchb, and prkcz. 
Figure 7. Prkcda expression in heart and otic 
vesicle 72 hpf. 
Prkcda CRISPR mutants 
CRISPR mutants were made by selecting guide RNAs with high predicted cutting efficiency for 
prkcda using ChopChop (https://chopchop.cbu.uib.no/).  Guide RNAs were injected with 
recombinant Cas9 protein, and a sample of F0 embryos were pooled and typed by next generation 
sequencing.  Sequencing data was analyzed using a custom pipeline to identify frameshift indel 
mutations.  Mutagenesis frequency was approximately 65% for frameshift indels (Figure 9).  These 
Figure 9. Prkcda sample 
sequences and mutagenesis. 
animals have been raised to adulthood and are being screened for germline transmission of 
frameshift alleles.    
 
Discussion 
 In an unperturbed state, prkcda exhibits low levels of expression in niche endothelial 
cells and high levels of expression in non-niche endothelial cells.  Overexpression of prkcda in 
the CHT, however, resulted in an increased number of HSCs within this microenvironment.  
Although a specific mechanism for prkcda signaling has yet to be uncovered, this modulation of 
HSCs within the niche suggests that prkcda has a regulatory role following its introduction into 
the microenvironment.  This revised role of prkcda upon overexpression may be the result of 
PKC crosstalk upon a change in microenvironment context, leading to altered downstream 
signaling of prkcda itself or among other PKC isoforms normally residing in the endothelial cell 
niche.  For example, Kim et al16 reported that mitogen-activated protein kinase (MAPK) 
modulation in cells containing PKCζ overexpression relied on conventional and novel PKC 
isoform expression as PKCζ is not responsive to DAG analogues.  Therefore, it is possible that 
there is an unidentified synergistic effect among PKC isozymes within the endothelial cell niche. 
The cxcl8/cxcr1/prkcda signaling pathway may support increased HSC numbers via 
endothelial niche remodeling.  Our lab has shown that human umbilical vein endothelial cell 
treatment with recombinant cxcl8 chemokines in vitro resulted in increased accumulation of 
PKC-protein.  Enforced expression of cxcl8 by HSPCs in Runx1+23:cxcl8  zebrafish embryos 
increased stem cell numbers.46  These results support the premise that PKC isoforms may 
function to enhance blood cell development only upon appropriate cytokine binding at the 
GPCR. 
The increase in endothelial-cell niche HSCs resulting from prkcda overexpression is 
intriguing given the isozyme’s common role in apoptotic pathways.  Recent experiments by the 
Blaser lab suggest that cxcl8/cxcr1 signaling within the niche may supplant apoptotic pathways 
involving phosphorylation of the kinase’s regulatory tyrosines, such as Tyr-187 and Tyr-64.  The 
upstream chemokine signaling and subsequent downstream kinase activity influencing stem cell 
production is perhaps due to the change in microenvironment context experienced by prkcda 
upon enforced expression in the CHT. 
Cxcl8 is associated with cell survival and signals through both the phosphoinositide-3-
kinase (PI3K) and MAPK signaling cascades.47  A study by Grossoni et al48 noted that PKCδ 
overexpression in murine NMuMG mammary cells led to cell proliferation and MAPK-ERK 
activation.  Importantly, the study’s authors highlighted that this isoform’s overexpression 
resulted in resistance to chemotherapy treatments.  Instead, stimuli associated with apoptosis had 
the unexpected effect of increasing cell proliferation.  PKCδ expression has a dual role of 
apoptosis and cell proliferation, depending on unique signaling within the microenvironment 
context.48  The cxcl8/cxcr1/prkcda pathway’s stimulation of endothelial cell niche expansion and 
increased HSPC cuddling in the Blaser lab experiments correlates with the findings by Grossoni 
and others that pertain to the gene’s role of positive regulation in certain contexts.  The role of 
this pathway in leukemogenesis is currently unclear, however.  
Based on 72 hpf quantification, enforced expression of other PKC genes (prkcaa, prkcdb, 
prkchb, and prkcz) within the niche did not cause a significant change in HSC numbers.  Initial 
data indicates a lack of significant differential expression among non-niche and niche endothelial 
cells.  The exact role of these PKC isozymes within the zebrafish CHT and their influence on 
HSC populations remains to be discovered.  The fact that prkcdb expression did not resemble 
that of its paralog, prkcda, is interesting and examination of the mutational differences between 
the two isoforms may further our understanding of prkcda’s dual role.  Future experiments 
involving the knockout of other PKC genes via the CRISPR-Cas9 system, in conjunction with 
enforced prkcda expression, may provide additional information on PKC functionality and 
crosstalk within the CHT. 
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